Concepedia

Lina Reslan

LR

Statistics

Publications

4

Citations

565

H-Index

4

Active since

2009

Affiliations

Inserm(Current)

Centre de Recherche en Cancérologie de Lyon

Hospices Civils de Lyon

Roche (Switzerland)

Université Claude Bernard Lyon 1

Lina Reslan is an author at Inserm specializing in immunology, cancer immunology, and rituximab-based therapy.

Publications per year

2009–2013

4

Publications

4

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl et al. · Molecular Cancer Therapeutics · 2013 · 359 citations

Pharmacy, Cell Biology, Immunology +17

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Stéphane Dalle, Lina Reslan, Timothee Besseyre de Horts et al. · Molecular Cancer Therapeutics · 2011 · 128 citations · Full text

Pharmacy, Immunology, Oncology +16

Transfection of cells in suspension by ultrasound cavitation

Lina Reslan, Jean‐Louis Mestas, Stéphanie Herveau et al. · Journal of Controlled Release · 2009 · 45 citations

Medicine, Bioengineering, Cell Biology +12

<i>In vivo</i>Model of Follicular Lymphoma Resistant to Rituximab

Stéphane Dalle, Sophie Dupire, Stéphanie Brunet-Manquat et al. · Clinical Cancer Research · 2009 · 33 citations

Medicine, Immunology, Oncology +15

1–4 of 4